ITGB1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma line, featuring disruption of the ITGB1 gene. This loss-of-function model provides a versatile tool for investigating integrin beta-1-dependent signaling in a widely used cancer cell background. The polyclonal format ensures a heterogeneous KO population, capturing a range of functional null alleles that collectively recapitulate the phenotypic consequences of ITGB1 deficiency without clonal artifacts.
HeLa cells are an immortalized epithelial line established from an HPV18-positive cervical carcinoma, characterized by anchorage-dependent growth and robust expression of integrin receptors. Their HPV-driven transformation creates a relevant oncogenic context for studying adhesion-mediated signaling pathways. These cells are well-suited for genetic manipulation and have been extensively employed in cancer biology, migration research, and drug screening, providing a reproducible platform for knockout studies.
ITGB1 encodes the integrin beta-1 subunit, which heterodimerizes with various alpha integrin partners (e.g., ITGA5, ITGAV) to form receptors for extracellular matrix proteins including fibronectin, laminin, and collagen. Ligand binding activates intracellular signaling cascades via focal adhesion kinase (FAK) and SRC, leading to downstream effectors such as PI3K/AKT and MAPK/ERK. Integrin beta-1 is regulated upstream by growth factors like TGFB1, EGF, and PDGF, and assembles complexes with talin, kindlin, paxillin, and vinculin to link the actin cytoskeleton. Downstream, these pathways control Rho GTPase activity, cyclin D1 expression, and transcriptional programs governing cell survival, proliferation, and migration.
In the HeLa context, ITGB1 knockout abrogates adhesion-dependent signaling, resulting in diminished cell attachment, impaired directional migration, and reduced phosphorylation of FAK (pFAK), AKT (pAKT), and ERK (pERK). This model permits dissection of integrin-specific contributions to oncogenic processes, separate from non-cancerous backgrounds, and helps clarify how viral oncoproteins intersect with adhesive networks. The loss of beta-1 integrin disrupts focal adhesion dynamics and cytoskeletal organization, enabling mechanistic studies of tumor cell dissemination.
Researchers can apply this knockout model in quantitative assays including wound healing, transwell migration, and cell adhesion to ECM substrates. It facilitates phospho-signaling analysis by western blotting, flow cytometric profiling of surface integrin levels, and immunofluorescence staining for focal adhesion markers like paxillin and vinculin. Key applications encompass metastasis research, drug resistance investigations, anti-metastatic compound screening, and 3D culture models that mimic tumor-microenvironment interactions. For technical inquiries or further details, please contact Ascent Research.
